Laurent Pharmaceuticals, a Montreal based clinical stage biopharmaceutical company has come up with an oral drug candidate, LAU-7b, to potentially treat COVID-19. The U.S. Food and Drug Administration (FDA) has granted Laurent Pharmaceuticals to begin enrolling U.S. patients in phase 2 of the clinical trial for LAU-7b which is called RESOLUTION. RESOLUTION will consist of  200 patients who are hospitalized for COVID-19, and they will receive either a daily placebo pill, or a daily LAU-7b pill for 14 days. Dr. Radu Pislariu MD, President and CEO of Laurent Pharmaceuticals explains that “The main objective of the RESOLUTION study is to demonstrate that LAU-7b is a safe and effective treatment option for COVID-19 patients that are at risk of lung complications because of their age, underlying condition or both”.

Read more here.

More on: